BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor
BRG1/BRM抑制剂靶向AML干细胞,与BET或menin抑制剂联合使用时,在临床前疗效显著优于其他抑制剂。
期刊:Blood
影响因子:23.1
doi:10.1182/blood.2023022832
Fiskus, Warren; Piel, Jessica; Collins, Mike; Hentemann, Murphy; Cuglievan, Branko; Mill, Christopher P; Birdwell, Christine E; Das, Kaberi; Davis, John A; Hou, Hanxi; Jain, Antrix; Malovannaya, Anna; Kadia, Tapan M; Daver, Naval; Sasaki, Koji; Takahashi, Koichi; Hammond, Danielle; Reville, Patrick K; Wang, Jian; Loghavi, Sanam; Sen, Rwik; Ruan, Xinjia; Su, Xiaoping; Flores, Lauren B; DiNardo, Courtney D; Bhalla, Kapil N